#ATS2019 – Randomized Trial: Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease
21 May, 2019 | 06:13h | UTCNintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Nintedanib slows lung function decline in SSc-associated interstitial lung disease – Medicine Matters (free)
Just Presented at the 2019 Meeting of the American Thoracic Society.